The landscape for biologics to treat patients with psoriasis looks excellent, said April Armstrong, MD, MPH, professor and chief of dermatology at UCLA.
April Armstrong, MD, MPH, professor and chief of dermatology at UCLA, highlights the different benefits of IL-17 and IL-23 inhibitors for treating patients with psoriasis.
Transcript
What are some main differences between IL-17 and IL-23 inhibitors, and is there a preference when treating psoriasis?
IL-23 and IL-17 inhibitors are excellent treatments for patients with moderate to severe plaque psoriasis. I think that one of the key differentiating factors between the 2 of them is that IL-17 inhibitors have very good response in psoriatic arthritis [PsA]; they work very well for both the peripheral as well as axial [PsA]. Now for the IL-23 inhibitors, most of them are also approved for PsA, so we do have some data in that regard as well, but I will say for someone who has severe [PsA], IL-17 inhibitors probably as a class work a bit better in that regard.
IL-23 inhibitors really shine in terms of their fantastic safety record, they are well tolerated by patients, and the safety profile over time is also very good. They also have long-term persistence in the real-world studies, which we have seen, and that is very helpful for patients because we want our patients to be able to not switch from one medication to another and be able to stay on the same medication as long as it works. And I think the IL-23 class as a whole have pretty good persistence of response. In addition to that, we also see that the IL-23 class of medications is really fantastic in terms of infrequent injections. The injection interval is usually between every 2 months to about every 3 months, so you really only get a few doses during the year.
Now, our newer IL-17 inhibitors, and I will say one that was just approved yesterday has the option of also doing 1 injection every 2 months, and that's bimekizumab. So, really hot off the press, we have a new IL-17 inhibitor that just got approved by the FDA. As you can see, the landscape for biologics for patients with psoriasis looks really excellent. We have a number of different options to offer for our patients as well as our clinicians.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More